Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Kiniksa Pharmaceuticals International, plc changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 127 | 1 | 134 | +8 |
| Shares | 31.8M | 1.52M | 34.9M | +4.60M (+15.2%) |
| Value | $447.7M | $21.4M | $605.8M | +$179.5M (+42.1%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pictet Asset Management Holding SA | 1,604,717 | $27.9M | 0.03% |
| Driehaus Capital Management LLC | 503,750 | $8.75M | 0.11% |
| Invesco Ltd. | 212,596 | $3.69M | 0.00% |
| EAM Investors, LLC | 124,438 | $2.16M | 0.42% |
| Arrowstreet Capital, Limited Partnership | 72,715 | $1.26M | 0.00% |
| Dark Forest Capital Management LP | 65,029 | $1.13M | 0.09% |
| Capula Management Ltd | 51,340 | $891.8K | 0.06% |
| Principal Financial Group Inc | 44,724 | $776.9K | 0.00% |
| Winton Group Ltd | 22,504 | $390.9K | 0.03% |
| Russell Investments Group, Ltd. | 20,814 | $362.6K | 0.00% |
| SEI Investments Co | 20,819 | $361.6K | 0.00% |
| QRG Capital Management, Inc. | 14,331 | $248.9K | 0.00% |
| Nebula Research & Development LLC | 13,686 | $237.7K | 0.13% |
| Victory Capital Management Inc | 10,106 | $175.5K | 0.00% |
| Globeflex Capital L P | 9,338 | $162.2K | 0.02% |
| Amundi | 5,770 | $94.1K | 0.00% |
| IFP Advisors, Inc | 3,750 | $65.1K | 0.00% |
| Lazard Asset Management LLC | 3,502 | $60.0K | 0.00% |
| CWM, LLC | 85 | $1.00K | 0.00% |
Sold out (11)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Woodline Partners LP | 290,001 | $4.08M |
| Renaissance Technologies LLC | 84,447 | $1.19M |
| PDT Partners, LLC | 40,439 | $569.4K |
| Cubist Systematic Strategies, LLC | 40,294 | $567.3K |
| Point72 Middle East FZE | 25,669 | $361.4K |
| Dynamic Technology Lab Private Ltd | 19,081 | $269.0K |
| MetLife Investment Management | 17,349 | $244.3K |
| Thrivent Financial for Lutherans | 11,025 | $155.0K |
| Cornerstone Investment Partners, LLC | 10,474 | $147.5K |
| 25 LLC | 36 | $501 |
| Allworth Financial LP | 23 | $324 |
Not filed for Q3 2023 yet (1)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 1,517,123 | $21.4M |